Alphatec Holdings saw its shares surge 9.5% in the most recent trading session, with volume topping the 30-day average by 45%. This spike coincided with analysts’ upward revisions to full-year revenue forecasts, driven by stronger demand for the company’s MIS spinal implant systems. Despite the bullish momentum, short interest remains elevated at 12.3% of the float, suggesting skepticism among hedge funds about sustained gains. Investors will be watching next week’s order backlog report–currently at $118 million–to gauge whether the rally can extend beyond this technical rebound.

Craig E. Hunsaker, Alphatec’s Executive Vice President of People and Culture, sold 32,584 shares on December 10, 2025, in a single transaction valued at $679,050.56. This divestiture trimmed his direct holdings by 2.53%, bringing his stake down to 1,256,558 shares. While insider sales can sometimes signal caution, Hunsaker cited portfolio diversification as his primary motivation. Following the sale, total insider ownership across Alphatec’s executive team remains above 8%, reflecting continued alignment with long-term corporate objectives.